Fig. 8

Fisetin promotes the osteogenic differentiation of BMSCs. A BMSCs were treated with increasing concentrations (0.1 μM, 0.5 μM, 1 μM, 5 μM, 10 μM, and 20 μM) of fisetin for 24, 48 and 72 h, followed by the determination of the OD value by CCK-8 assay. Cell viability was expressed as the mean ± SD from four independent experiments. Compared with the Concurrent DMSO group, *p < 0.05. B The ALP activity of BMSCs was expressed as the mean ± SD from three independent data points. Compared with the DMSO group, *p < 0.05; **p < 0.01. C, D BMSCs were treated with fisetin for 48 h, and mRNA expression was determined by RT–PCR. The relative mRNA expression of ALP, Collagen I, RUNX2 and Osteopontin was normalized to GAPDH. Compared with the DMSO group, *p < 0.05; **p < 0.01. E BMSCs were treated with fisetin for 48 h, followed by the analysis of collagen I, RUNX2 and osteopontin protein expression levels with WB. F Comparative analysis of grayscale values of relevant protein bands was performed, and the values were expressed as the mean ± SD from three independent experiments. Compared with the DMSO group, *p < 0.05; **p < 0.01; ***p < 0.001